Lacosamide as a first-line treatment option in focal epilepsy: a cost-utility analysis for the Greek healthcare system

Abstract

Lacosamide is a cost-effective option at a willingness-to-pay threshold of €30,000 per QALY, representing a valuable monotherapy treatment option for patients with focal epileptic seizures in the Greek setting.